In a report released on January 4, Jailendra Singh from Truist Financial maintained a Buy rating on Privia Health Group (PRVA – Research Report), with a price target of $32.00. The company’s shares closed last Friday at $21.29.
According to TipRanks, Singh is an analyst with an average return of -15.2% and a 33.54% success rate. Singh covers the Healthcare sector, focusing on stocks such as R1 RCM, Evolent Health, and Agilon Health.
Privia Health Group has an analyst consensus of Strong Buy, with a price target consensus of $31.54, a 48.14% upside from current levels. In a report released on January 5, BTIG also maintained a Buy rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $30.15 and a one-year low of $19.68. Currently, Privia Health Group has an average volume of 743.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Privia Health Group (PRVA) Company Description:
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
Read More on PRVA:
- Privia Health to Participate in the J.P. Morgan Healthcare Conference
- 3 Best Stocks to Buy Now, 12/7/2023, According to Top Analysts
- Privia Health initiated with bullish view at JMP Securities, here’s why
- Privia Health price target lowered to $38 from $43 at JPMorgan
- Privia Health price target lowered to $32 from $36 at Truist
